ArticleImmunoTargets and therapy2026
Unveiling a ceRNA Network Involving IL-8 and TNF-α in Active Generalized Vitiligo by Multi-Omics Integration.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Active generalised vitiligo (AGV) is an autoimmune disorder characterised by progressive melanocyte loss. However, the molecular mechanisms underlying AGV, particularly the roles of non-coding RNAs and their interaction with proteomic changes, remain poorly understood. The aim of this study was to systematically identify key regulatory networks and molecular changes in AGV by integrating proteomic and whole-transcriptome data. Methods: Data-independent acquisition mass spectrometry (DIA-MS) and whole transcriptome sequencing (WTS) were performed on whole blood samples from three AGV patients and three healthy individuals (HIs). Bioinformatic analyses were then used to identify differentially expressed proteins (DEPs), messenger RNAs (mRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and microRNAs (miRNAs). Co-expression and competing endogenous RNA (ceRNA) networks were constructed and visualised using Cytoscape. Key hub genes and cytokine levels were then validated using quantitative reverse transcription PCR (qRT-PCR) and immunoassays in an independent cohort. Results: We identified 15 DEPs and 669 differentially expressed mRNAs (DEmRNAs), as well as significant alterations in 258 lncRNAs, 29 miRNAs and 44 circRNAs in AGV. Functional enrichment analysis revealed their involvement in chemokine signaling and lysosomal pathways. Protein-protein interaction network analysis revealed ten hub genes, including CXCL8, CXCR1, CXCR2 and IL1R2. We established a core ceRNA regulatory network featuring long non-coding RNAs (eg NUTM2B-AS1, LINC00894), circular RNAs (eg ASAP1, CDR2) and microRNAs (eg hsa-mir-3613-3p, hsa-mir-511-5p) that potentially modulate inflammatory responses. Experimental validation confirmed significantly elevated levels of the pro-inflammatory cytokines IL-8 and TNF-α in AGV patients, and qRT-PCR results for nine of the ten hub genes were consistent with the sequencing data. Conclusion: Our integrated multi-omics analysis uncovers a novel ceRNA network and highlights the significant upregulation of IL-8 and TNF-α in AGV. These findings provide new insights into the post-transcriptional regulatory mechanisms and inflammatory pathways driving AGV and offer potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.